Literature DB >> 23298160

A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.

Ann Apolloni1, Min-Husan Lin, Haran Sivakumaran, Dongsheng Li, Michael H R Kershaw, David Harrich.   

Abstract

Here we show potent inhibition of HIV-1 replication in a human T cell line and primary human CD4(+) cells by expressing a single antiviral protein. Nullbasic is a mutant form of the HIV-1 Tat protein that was previously shown to strongly inhibit HIV-1 replication in nonhematopoietic cell lines by targeting three steps of HIV-1 replication: reverse transcription, transport of viral mRNA, and trans-activation of HIV-1 gene expression. Here we investigated gene delivery of Nullbasic, using lentiviral and retroviral vectors. Although Nullbasic could be delivered by lentiviral vectors to target cells, transduction efficiencies were sharply reduced primarily because of negative effects on reverse transcription mediated by Nullbasic. However, Nullbasic did not inhibit transduction of HEK293T cells by a murine leukemia virus (MLV)-based retroviral vector. Therefore, MLV-based virus-like particles were used to transduce and express Nullbasic-EGFP or EGFP in Jurkat cells, a human leukemia T cell line, and Nullbasic-ZsGreen1 or ZsGreen1 in primary human CD4(+) cells. HIV-1 replication kinetics were similar in parental Jurkat and Jurkat-EGFP cells, but were strongly attenuated in Jurkat-Nullbasic-EGFP cells. Similarly, virus replication in primary CD4(+) cells expressing a Nullbasic-ZsGreen1 fusion protein was inhibited by approximately 8- to 10-fold. These experiments demonstrate the potential of Nullbasic, which has unique inhibitory activity, as an antiviral agent against HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23298160      PMCID: PMC3696950          DOI: 10.1089/hum.2012.176

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  41 in total

1.  Is green fluorescent protein toxic to the living cells?

Authors:  H S Liu; M S Jan; C K Chou; P H Chen; N J Ke
Journal:  Biochem Biophys Res Commun       Date:  1999-07-14       Impact factor: 3.575

2.  Tat is required for efficient HIV-1 reverse transcription.

Authors:  D Harrich; C Ulich; L F García-Martínez; R B Gaynor
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells.

Authors:  Greg M Podsakoff; Barbara C Engel; Denise A Carbonaro; Chris Choi; Elzbieta M Smogorzewska; Gerhard Bauer; David Selander; Susan Csik; Kathy Wilson; Michael R Betts; Richard A Koup; Gary J Nabel; Keith Bishop; Steven King; Manfred Schmidt; Christof von Kalle; Joseph A Church; Donald B Kohn
Journal:  Mol Ther       Date:  2005-07       Impact factor: 11.454

4.  Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems.

Authors:  S Swift; J Lorens; P Achacoso; G P Nolan
Journal:  Curr Protoc Immunol       Date:  2001-05

5.  Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells.

Authors:  R H Stauber; E Afonina; S Gulnik; J Erickson; G N Pavlakis
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

6.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.

Authors:  R Zufferey; D Nagy; R J Mandel; L Naldini; D Trono
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

7.  WZsGreen/+: a new green fluorescent protein knock-in mouse model for the study of KIT-expressing cells in gut and cerebellum.

Authors:  Mira Wouters; Karine Smans; Jean-Marie Vanderwinden
Journal:  Physiol Genomics       Date:  2005-06-14       Impact factor: 3.107

8.  Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis.

Authors:  Richard J Fish; Egbert K O Kruithof
Journal:  Exp Cell Res       Date:  2005-12-05       Impact factor: 3.905

9.  Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals.

Authors:  U Ranga; C Woffendin; S Verma; L Xu; C H June; D K Bishop; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

10.  Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro.

Authors:  David Warrilow; Luke Meredith; Adam Davis; Christopher Burrell; Peng Li; David Harrich
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

View more
  14 in total

1.  A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.

Authors:  Min-Hsuan Lin; Ann Apolloni; Vincent Cutillas; Haran Sivakumaran; Sally Martin; Dongsheng Li; Ting Wei; Rui Wang; Hongping Jin; Kirsten Spann; David Harrich
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

2.  Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex.

Authors:  Warachai Praditwongwan; Phimonphan Chuankhayan; Somphot Saoin; Tanchanok Wisitponchai; Vannajan Sanghiran Lee; Sawitree Nangola; Saw See Hong; Philippe Minard; Pierre Boulanger; Chun-Jung Chen; Chatchai Tayapiwatana
Journal:  J Comput Aided Mol Des       Date:  2014-07-05       Impact factor: 3.686

3.  Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.

Authors:  Sizhu Duan; Xin Yu; Chu Wang; Lina Meng; Yanxin Gai; Yan Zhou; Tiejun Gu; Bin Yu; Jiaxin Wu; Xianghui Yu
Journal:  J Virol       Date:  2022-08-11       Impact factor: 6.549

4.  Differential Effects of Strategies to Improve the Transduction Efficiency of Lentiviral Vector that Conveys an Anti-HIV Protein, Nullbasic, in Human T Cells.

Authors:  Lina Rustanti; Hongping Jin; Dongsheng Li; Mary Lor; Haran Sivakumaran; David Harrich
Journal:  Virol Sin       Date:  2018-03-14       Impact factor: 4.327

Review 5.  Bone Marrow Gene Therapy for HIV/AIDS.

Authors:  Elena Herrera-Carrillo; Ben Berkhout
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

6.  Nucleolar Localization of HIV-1 Rev Is Required, Yet Insufficient for Production of Infectious Viral Particles.

Authors:  Jerlisa Ann C Arizala; Mayumi Takahashi; John C Burnett; Dominique L Ouellet; Haitang Li; John J Rossi
Journal:  AIDS Res Hum Retroviruses       Date:  2018-07-05       Impact factor: 2.205

7.  Binding of the eukaryotic translation elongation factor 1A with the 5'UTR of HIV-1 genomic RNA is important for reverse transcription.

Authors:  Dongsheng Li; Ting Wei; Hongping Jin; Amanda Rose; Rui Wang; Min-Hsuan Lin; Kirsten Spann; David Harrich
Journal:  Virol J       Date:  2015-08-06       Impact factor: 4.099

8.  A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1.

Authors:  Min-Hsuan Lin; Haran Sivakumaran; Alun Jones; Dongsheng Li; Callista Harper; Ting Wei; Hongping Jin; Lina Rustanti; Frederic A Meunier; Kirsten Spann; David Harrich
Journal:  Retrovirology       Date:  2014-12-14       Impact factor: 4.602

9.  Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein.

Authors:  Hongping Jin; Dongsheng Li; Haran Sivakumaran; Mary Lor; Lina Rustanti; Nicole Cloonan; Shivangi Wani; David Harrich
Journal:  MBio       Date:  2016-07-05       Impact factor: 7.867

10.  A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes.

Authors:  Lina Rustanti; Hongping Jin; Mary Lor; Min Hsuan Lin; Daniel J Rawle; David Harrich
Journal:  Virol J       Date:  2017-03-14       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.